The data from several recent monoclonal antibody clinical trials for multiple myeloma (MM), which are producing very exciting results, was presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. In this interview, Alberto Rocci, MD from Central Manchester University Hospital, Manchester, UK discusses the current CASTOR (NCT02136134) and ELOQUENT-2 (NCT01239797) Phase III clinical trials, which are investigating the addition of monoclonal antibodies to traditional treatment regimens for relapsed refractory MM. Dr Rocci gives a summary of the treatment combinations, results in high-risk cytogenetics groups and the toxicity profiles of the drugs. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.
Unprecedented clinical trial results for MM
